600422 KPC Pharmaceuticals, Inc.
- 23.28
- -0.11-0.47%
KPC Pharmaceuticals, Inc. News
Despite Lower Earnings Than Three Years Ago, KPC PharmaceuticalsInc (SHSE:600422) Investors Are up 155% Since Then
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more tha
Earnings Tell The Story For KPC Pharmaceuticals,Inc (SHSE:600422)
KPC Pharmaceuticals,Inc's (SHSE:600422) price-to-earnings (or "P/E") ratio of 36.6x might make it look like a sell right now compared to the market in China, where around half of the companies have P
China Resources Pharmaceutical (03320.HK): KPC achieved total revenue of 1,853 billion yuan in the first quarter
Gelonghui, April 22 | China Resources Pharmaceutical (03320.HK) announced that in the first quarter of 2024, KPC achieved total operating revenue of 1,853 billion yuan, a decrease of 3% year on year; net profit of 121 million yuan, a decrease of 10% year on year.
Kunming Pharmaceutical Group (600422.SH) reported first-quarter results, net profit of 119 million yuan, a year-on-year decrease of 9.41%
Kunming Pharmaceutical Group (600422.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Kunyao Group Receives Clinical Trial Approval for FMF Drug
China's National Medical Products Administration has approved Kunyao Group's (SHA:600422) plan to carry out a clinical trial of its drug against familial Mediterranean fever of FMF, according to a Wed
Kunming Pharmaceutical Group (600422.SH): “KPC-149 Oral Solution” approved to carry out related clinical trials
Kunming Pharmaceutical Group (600422.SH) announced that the company recently received KPC- issued by the State Drug Administration...
Kunming Pharmaceutical Group (600422.SH): Obtained Drug Clinical Trial Approval Notice
Gelonghui, April 16 | Kunming Pharmaceutical Group (600422.SH) announced that the company recently received the “Drug Clinical Trial Approval Notice” for the KPC-149 oral solution (Notification Number: 2024LP00909, referred to as “the new drug”) from the State Drug Administration in accordance with Class 2.2 improved new drug, and agreed to carry out related clinical trial research on the new drug. KPC-149 oral solution is a Class 2.2 improved new drug developed by the company. The indications are: Familial Mediterranean Fever.
KPC PharmaceuticalsInc's (SHSE:600422) Shareholders May Want To Dig Deeper Than Statutory Profit
Following the solid earnings report from KPC Pharmaceuticals,Inc (SHSE:600422), the market responded by bidding up the stock price. However, we think that shareholders should be cautious as we found
KPC Pharmaceuticals,Inc's (SHSE:600422) Market Cap Surged CN¥560m Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Key Insights KPC PharmaceuticalsInc's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 51% of the business is held by
China Resources Pharmaceutical (03320.HK): KPC's net profit in 2023 increased 16.05% year-on-year to 445 million yuan
Gelonghui, March 22 | China Resources Pharmaceutical (03320.HK) announced that in 2023, Kunyao Pharmaceutical Group (600422.SH) achieved operating income of RMB 7.703 billion, down 6.99% year on year; net profit attributable to shareholders of listed companies was 445 million yuan, up 16.05% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 335 million, up 33.45% year on year; basic earnings per share were 0.59 yuan.
Is KPC PharmaceuticalsInc (SHSE:600422) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
KPC Pharmaceuticals,Inc's (SHSE:600422) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock?
KPC PharmaceuticalsInc's (SHSE:600422) stock is up by 4.3% over the past month. However, the company's financials look a bit inconsistent and market outcomes are ultimately driven by long-term funda
China Resources Pharmaceuticals: China Resources 39 expects net profit to increase to RMB 2,818 billion to RMB 3,065 billion in 2023
China Resources Pharmaceutical (03320) announced that China Resources Pharmaceutical (03320), a subsidiary of the company, expects net profit attributable to shareholders of approximately RMB 2,818 billion to RMB 3,065 billion in 2023 (same period of the previous year: net profit of approximately RMB 2,449 million), and net profit attributable to shareholders of China Resources 39 after deducting non-recurring profit and loss is estimated to be approximately RMB 2,688 million (same period last year: net profit of approximately RMB 2,219 million); basic earnings per share are expected to be approximately RMB 2.87 billion to RMB 3.12 billion (above) Year in year: profit of approximately RMB
KPC PharmaceuticalsInc (SHSE:600422) Sheds 7.1% This Week, as Yearly Returns Fall More in Line With Earnings Growth
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. One great example is KP
Kunming Pharmaceutical Group (600422.SH): KPC-149 oral solution drug clinical trial application accepted
Kunming Pharmaceutical Group (600422.SH) issued an announcement. The company recently received the “Subject...” issued by the State Drug Administration
Kunming Pharmaceutical Group (600422.SH): Application for marketing licensing of sevilamycin carbonate suspensions accepted
On January 4, Ge Longhui Pharmaceutical Group (600422.SH) announced that its wholly-owned subsidiary Kunming Beck Norton Pharmaceutical Co., Ltd. recently received the “Notice of Acceptance” issued by the State Drug Administration, and the company's drug marketing license application for sevilamgane carbonate suspension was accepted by the State Drug Administration. Sevelam carbonate tablets were developed by Genzyme and first approved for marketing in the US in 2007; later, the company developed dry suspensions and were approved for marketing in the US and the European Union in 2009, respectively, for the control of hyperphosphatemia in patients with chronic kidney disease. Compared to sevelam carbonate tablets, dry suspensions are more
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 34x, you may consider KPC Pharmaceuticals,Inc (SHSE:600422) as a stock to potentially avoid with its 39.9x P/
KPC Pharmaceuticals,Inc's (SHSE:600422) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 4.5% Last Week
Key Insights Significant control over KPC PharmaceuticalsInc by retail investors implies that the general public has more power to influence management and governance-related decisions The top 8 sha
KPC Pharmaceuticals,Inc's (SHSE:600422) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
KPC PharmaceuticalsInc's (SHSE:600422) stock is up by a considerable 22% over the past three months. But the company's key financial indicators appear to be differing across the board and that makes
[BT Financial Report Instantaneous Analysis] Kunyao Group's 2023 Three-Quarter Report: Balance Ratio Declines, Operating Income and Net Profit Maintain Steady Growth
This financial report was announced at 18:29:53 2023-10-27 18:29:53 Kunyao Group (stock code: 600422) is a company operating in the pharmaceutical manufacturing sector. Its core business includes drug research and development, production and sales, covering the entire pharmaceutical industry chain. Based in mainland China, the company actively carries out a global layout, responds to national policies, and strengthens traditional Chinese medicine technology inheritance and innovation, talent development, service model innovation, and management system innovation. In terms of assets and liabilities, the total assets of the Kunyao Group at the end of the third quarter of 2023 were 9.291 billion yuan, compared with 9.432 billion yuan at the end of the previous year
Analysis
Price Target
No Data
